Research programme: HIV protease inhibitors - GlaxoSmithKline

Drug Profile

Research programme: HIV protease inhibitors - GlaxoSmithKline

Alternative Names: SKF 107461; SKF 108370; SKF 108842

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 01 Oct 1998 Preclinical development for HIV infections treatment in USA (unspecified route)
  • 10 Jul 1996 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top